Indian drugmakers to see FY25 revenue boost in key US market, says India Ratings and Research

  • 📰 SaltWire Network
  • ⏱ Reading Time:
  • 29 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 63%

United States News News

United States United States Latest News,United States United States Headlines

Explore stories from Atlantic Canada.

Keegan Matheson on Blue Jays, Baseball Memories, and More | SaltWire #writer #torontobluejays #mlbHYDERABAD - Indian drugmakers, which have the U.S. market as a key segment, will sustain their revenue improvement in fiscal 2025 due to drug shortages in the United States, Mumbai-based India Ratings and Research said on Monday.

There is an active shortage of 233 drugs across 22 therapeutic categories as of April, led mainly by discontinuing production of some drugs, rising demand and delays in shipments, it said, also citing data from the U.S. Food and Drug Administration. Reddy's reported a 29% jump in North America sales for the most recent quarter ended March 31, while Cipla saw an 11% jump in revenue from the region.India Ratings and Research said increasing regulatory costs led to many US-based generic pharma manufacturers halting the production of certain drugs.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 45. in US
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United States United States Latest News, United States United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Emerging-Market Trio Gets Credit-Ratings Boost on Policy TurnsMarkets in three of the largest emerging economies got a boost after Turkey’s sovereign rating was upgraded, and as the outlooks for both Egypt and Nigeria were lifted.
Source: BNNBloomberg - 🏆 83. / 50 Read more »